Arrivo Bio to Participate in Fireside Chat at the Piper Sandler Virtual CNS Symposium
Arrivo Bio, a clinical-stage biopharmaceutical company developing first-of-its-kind medicines targeting the root cause
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Arrivo Bio, a clinical-stage biopharmaceutical company developing first-of-its-kind medicines targeting the root cause of hard-to-treat diseases, today announced that Steve Butts, Co-founder and Chief Executive Officer, and Joel Raskin, Chief Medical Officer will participate in a virtual fireside chat discussing forvisirvat, the company’s novel potential treatment for major depressive disorder, at the Piper Sandler Virtual CNS Symposium on Friday, August 14th at 10:30 a.m. ET.
For additional details or to request access to the webcast, please contact your Piper Sandler representative.
About Arrivo Bio
Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260813604345/en/
Media gallery
